Healthcare Industry News: dilatation catheter
News Release - February 28, 2011
OrbusNeich Announces Availability of Next-Generation Sapphire II Coronary Dilatation CatheterLatest Innovations Designed to Optimize Treatment of Challenging Lesions
HONG KONG, Feb. 28, 2011 -- (Healthcare Sales & Marketing Network) -- OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark (Conformite Europeenne) approval.
"I was impressed by the crossability of Sapphire II through the stent struts in a difficult left main bifurcation procedure," said Dr. Pieter Stella, head of the interventional catheterization laboratory at the University Medical Centre (UMC), Utrecht, the Netherlands.
Al Novak, OrbusNeich's chairman and CEO, said, "Sapphire II offers interventional cardiologists an exciting new technology to address the challenges of tight and complex lesions. Sapphire II reflects OrbusNeich's continued commitment to the innovation and development of high-performance balloon catheters."
Dr. Toshiya Muramatsu, director of the cardiology department at Saiseikai Yokohamashi Tobu Hospital in Yokohama-City, Japan, added, "The thin tip and new coating applied from the tip to the shaft contribute a great deal to the crossing performance of the Sapphire II. The crossability of Sapphire II can compete just as well, if not better, than any balloon on the market. I would not hesitate to recommend it for use in any CTO (chronic total occlusion) case."
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.